Trump administration announces drug pricing deals with CSL, Astellas and others

Trump administration announces drug pricing deals with CSL, Astellas and others  Reuters

Trump Administration Reaches Drug Pricing Deals With 9 Companies  WSJ

The new agreements bring the total number of companies in the administration's most-favored-nation pricing program to 26

The White House said the agreements will reduce costs to treat Parkinson's disease, macular degeneration, glaucoma, liver disease and other illnesses.

The Trump administration on Monday announced new Medicaid drug pricing agreements with nine mid-sized biotechnology and pharmaceutical companies.  Every drug “will be at the lowest prices available anywhere in the world,” President Trump said in the Oval Office, surrounded by company executives.   Under the agreements,

The Trump administration has struck new drug pricing agreements with nine biotech and pharmaceutical companies including UCB SA, Bridgebio Pharma Inc. and Sun Pharmaceutical Industries Ltd.

The string of deals builds on the Trump administration's push to link the nation's drug prices to cheaper ones abroad.

Ahead of the midterm elections, the Trump administration is seeking to increase affordability, a term the president has waved off as a Democratic “hoax.”